SCHEMBL14770613

SCHEMBL14770613

COc1ccc(C(C)c2nc3cc(Br)ccc3[nH]2)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ FLT3 P36888 1/20 0.40
▸ PTGES O14684 1/20 0.39
▸ ALOX5 P09917 1/20 0.39
▸ LTC4S Q16873 1/20 0.39
▸ KDM4E B2RXH2 2/20 0.38
▸ LMNA P02545 2/20 0.38
▸ HSD17B10 Q99714 1/20 0.38
▸ IDO1 P14902 1/20 0.37
▸ CYP1A2 P05177 2/20 0.37
▸ CYP2E1 P05181 2/20 0.37
▸ CYP3A4 P08684 2/20 0.37
▸ CYP2C8 P10632 2/20 0.37
▸ CYP2D6 P10635 2/20 0.37
▸ CYP2C9 P11712 2/20 0.37
▸ CYP2B6 P20813 2/20 0.37
▸ CYP2C19 P33261 2/20 0.37
▸ MAPT P10636 1/20 0.36
▸ COMT P21964 2/20 0.36
▸ RAB9A P51151 2/20 0.36
▸ NPC1 O15118 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14770549 0.89 ALDH1A1 (0.42) PTGESALOX5LTC4SKDM4ELMNA
SCHEMBL14770608 0.86 MLKL (0.48) FLT3IDO1CYP1A2CYP2E1CYP3A4
SCHEMBL14770492 0.84 AMY1A (0.41) FLT3PTGESALOX5LTC4SKDM4E
SCHEMBL14770550 0.84 FLT3 (0.40) FLT3PTGESALOX5LTC4SKDM4E
SCHEMBL14770535 0.82 MEN1 (0.53) PTGESALOX5LTC4SKDM4ELMNA
SCHEMBL14770646 0.82 SCN10A (0.40) PTGESALOX5LTC4SKDM4ELMNA
SCHEMBL14770638 0.81 SCN10A (0.52) PTGESALOX5LTC4SKDM4ELMNA
SCHEMBL14770612 0.81 CFB (0.43) PTGESALOX5LTC4SKDM4ELMNA
SCHEMBL14770640 0.81 SCN10A (0.44) PTGESALOX5LTC4SRAB9AMEN1
SCHEMBL14770674 0.81 SMN1; SMN2 (0.56) PTGESALOX5LTC4SKDM4EIDO1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9096531-B2 Fused imidazole derivative TOA EIYO LTD. (JP) 2015-08-04 — — US disclosed
US-20130065896-A1 FUSED IMIDAZOLE DERIVATIVE TOA EIYO LTD. (JP) 2013-03-14 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130065896-A1 FUSED IMIDAZOLE DERIVATIVE CACNA1E, CACNA1G, CACNA1A FLT3 1912/4885PTGES 1148/4885ALOX5 3826/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback